StockData

Gyre Therapeutics vs Arcus Biosciences

GYRE and RCUS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GYRE and RCUS compare

Arcus Biosciences is the larger company, worth 4.1 times as much as Gyre Therapeutics ($2.1B against $508M).

Gyre Therapeutics grew revenue faster over the last twelve months (−3.7% versus −55.3% for Arcus Biosciences).

Gyre Therapeutics keeps more of each dollar of sales as profit, with a net margin of −33.9% compared with −393% at Arcus Biosciences.

Gyre Therapeutics scores higher on the StockData Score (11 against 3 for Arcus Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGYRERCUS
Size and price
Market cap$508M$2.1B
Share price$4.56$16.39
Change, 1 year−42.9%−18.3%
Change, 5 years−75.7%−64.6%
Beta (5Y)1.211.13
Employees618601
StockData Score
Total score11 (better)3
Valuation score1 (better)0
Growth score12 (better)
Performance score3 (better)0
Health score6 (better)1
Dividend score00
Valuation
P/S4.7× (better)17.8×
P/B4.7×4.5× (better)
FCF yield−1.5% (better)−22.8%
Fair value$5.29$7.34
Margin of safety13.8% (better)−123%
Growth
Revenue growth (TTM)−3.7% (better)−55.3%
Revenue growth, 5Y average41.0% (better)25.9%
Net income growth (TTM)−801%–
Profitability
Gross margin93.4%–
Operating margin−14.4% (better)−415%
Net margin−33.9% (better)−393%
FCF margin−7.2% (better)−406%
Return on equity−34.9% (better)−90.8%
Return on invested capital−26.6%–
Financial health
Debt / equity0.00–
Interest coverage–−44.2×
Current ratio4.32 (better)3.82
Altman Z-score8.53 (better)−0.74
Piotroski F-score5 (better)1
Dividends and buybacks
Buyback yield–−13.8%
Shareholder yield0.00% (better)−13.8%
Ownership
Held by institutions7.8%96.3%
Held by insiders93.8%31.7%
Insider net buying, 12 months−$953K (better)−$9.3M
Short interest, % of float32.4%15.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.